The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study

Abstract

These data show that the burden of CDI is considerable in Spain and Italy. Treatments that can reduce LOS, disease severity, and recurrence rates, as well as effective infection control measures to prevent transmission, have the potential to reduce the burden of CDI.

Attributable Cost ofClostridium difficileInfection in Pediatric Patients

“…The contrast of the findings from our 2 models-1 adjusting for LOS and 1 not adjustingconfirm and extend the findings of previous studies demonstrating that LOS is indeed an important consideration when calculating the attributable cost of CDI. 29 We also found that children with a diagnosis of CDI had a total LOS that was 4 days longer than children without CDI, even using a cohort of cases and controls that were matched by propensity to develop CDI. Given that we did not have access to the timing of diagnosis, we cannot conclude definitively that this increase in LOS is specifically a consequence of CDI, nor can we distinguish between community-associated (CA-CDI) versus hospital onset (HO-CDI) infection.…”

“…In a recent study from Europe, the increase in LOS attributable to CDI among a cohort of 19 children was 5 days; this value is similar to our estimate for children in the United States. 29 Our study adds to the very limited literature regarding the economic burden of pediatric CDI. Nylund et al 30 examined KID data from 1997 through 2006, and they reported descriptive median hospitalization charges in 2006 to be $10,893 in patients without CDI versus $31,957 in CDI patients.…”

Il Costo Ospedaliero di Trattamento di un Episodio di Infezione da Clostridium Difficile in Italia

“…Infine, anche se i centri ospedalieri partecipanti non garantiscono una totale rappresentatività del territorio nazionale, in quanto situati nel Nord e Centro Italia, quantomeno la numerosità dei soggetti arruolati è risultata superiore a quella di precedenti esperienze, consentendo quindi di fornire una più robusta stima del costo medio per episodio (7,11).…”

Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection

“…Recent model-based estimates place the 2014 economic cost of CDI at $5.4 billion in the United States, mostly attributable to hospitalization [ 13 ]. In Europe, extra per-patient costs for treatment of CDI were reported to reach €4396 to €14023, with the majority of costs due to hospitalization [ 14 , 15 ]. In France, 12.5% of the €163.1 million extra cost of CDI in public acute-care hospitals was attributable to rCDI [ 15 ].…”